跳至主要内容
临床试验/CTRI/2026/02/104015
CTRI/2026/02/104015尚未招募不适用

To Study The Role Of KIM-1 And NGAL Biomarker Based Prediction Of Renal Injury In Type 2 Diabetic Nephropathy

Dr Shivam Sanjay Mudkhede1 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2026年3月14日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
86
试验地点
1

研究概览

简要总结

Diabetic Nephropathy is a leading cause of Chronic Kidney Disease and End Stage Renal Disease and its detection is crucial for timely intervention and prevention of progression to end stage renal disease. So incorporating these biomarkers such as NGAL and KIM-1 is essential and help in better outcomes in patients with type 2 diabetes mellitus.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Adults aged between 18 and 80 years Diagnosed cases of Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association criteria Willingness to participate and provide written informed consent.

排除标准

  • Patients with chronic kidney disease (CKD) due to causes other than diabetic nephropathy like glomerulonephritis, polycystic kidney disease, obstructive uropathy Acute kidney injury or any recent acute illness affecting renal function Active urinary tract infections Current or recent use of nephrotoxic drugs, such as prolonged use of nonsteroidal anti-inflammatory drugs, aminoglycosides, or contrast agents History of malignancy or undergoing chemotherapy Patients with severe liver disease, heart failure, or other systemic inflammatory conditions.
  • Pregnant or lactating women Age below 18 years or above 80 years Refusal to provide informed consent.

研究者

发起方
Dr Shivam Sanjay Mudkhede
申办方类型
Private medical college
责任方
Principal Investigator
主要研究者

Dr Mudhkede Shivam Sanjay

KAHERs Jawaharlal Nehru Medical College

研究点 (1)

Loading locations...

相似试验